• LAST PRICE
    20.3200
  • TODAY'S CHANGE (%)
    Trending Up0.2600 (1.2961%)
  • Bid / Lots
    20.2700/ 1
  • Ask / Lots
    20.3200/ 2
  • Open / Previous Close
    19.9200 / 20.0600
  • Day Range
    Low 19.9200
    High 20.3200
  • 52 Week Range
    Low 7.4100
    High 24.1700
  • Volume
    45,598
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 20.06
TimeVolumeKURA
09:32 ET263319.92
09:34 ET10020.03
09:36 ET10020.11
09:38 ET10019.92
09:41 ET33519.98
09:45 ET110019.99
09:48 ET90020
09:52 ET283220.06
09:54 ET20020.08
09:56 ET363920.11
09:59 ET1102220.265
10:01 ET327320.26
10:03 ET208920.28
10:06 ET362820.32
10:08 ET10020.32
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKURA
Kura Oncology Inc
1.5B
-9.8x
---
United StatesSLNO
Soleno Therapeutics Inc
1.5B
-15.3x
---
United StatesNMRA
Neumora Therapeutics Inc
1.5B
-4.0x
---
United StatesEWTX
Edgewise Therapeutics Inc
1.6B
-11.2x
---
United StatesDAWN
Day One Biopharmaceuticals Inc
1.4B
-7.2x
---
United StatesGYRE
Gyre Therapeutics Inc
1.4B
-0.8x
---
As of 2024-04-30

Company Information

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Contact Information

Headquarters
12730 HIGH BLUFF DRIVE, SUITE 400SAN DIEGO, CA, United States 92130
Phone
858-500-8800
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer
Troy Wilson
Chief Operating Officer
Kathleen Ford
Chief Medical Officer
Stephen Dale
Chief Commercial Officer
Brian Powl
Chief Legal Officer, Secretary
Teresa Bair

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.5B
Revenue (TTM)
$0.00
Shares Outstanding
76.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.88
EPS
$-2.08
Book Value
$5.34
P/E Ratio
-9.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.